as attached
Abdulwahab Kammon(1-2010)

Live vaccines against fowlpox virus, which causes moderate pathology in poultry and is the type species of the Avipoxvirus genus, were developed in the 1920s. Development of recombinant fowlpox virus vector vaccines began in the 1980s, for use not only in poultry, but also in mammals including humans. In common with other avipoxviruses, such as canarypox virus, fowlpox virus enters mammalian cells and expresses proteins, but replicates abortively. The use of fowlpox virus as a safe vehicle for expression of foreign antigens and host immunomodulators, is being evaluated in numerous clinical trials of vaccines against cancer, malaria, tuberculosis and AIDS, notably in heterologous prime–boost regimens. In this article, technical approaches to, and issues surrounding, the use of fowlpox virus as a recombinant vaccine vector in poultry and mammals are reviewed.
Ibrahim Eldaghayes(1-2014)

Coronavirus disease 2019 (COVID-19) is a pandemic that affected almost all countries worldwide with more than 29,439,120 confirmed cases and 932,486 deaths recorded till on September 14, 2020. However, on May 25, 2020, after 2 months from the first reported case of COVID-19 in Libya, the country was among very few countries in the world that had very few cases of COVID-19 with a total of 75 confirmed cases and three deaths during the first 2 months since the detection of the first case on March 24, 2020. Based on the global epidemiological pattern of the disease, the magnitude of COVID-19 in Libya could have been much worse. However, the reality is eccentrically different and the epidemiology exhibited different scenario with very few cases being recorded during the first 2 months of pandemic in Libya. In this article, a review of COVID-19 situation in Libya is presented with thoughts about the potential reasons that could explain the very few cases of COVID-19 in the country in context with the global figures of the pandemic.
Ibrahim Eldaghayes(11-2020)